Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GDUFA Plus One: Stakeholders, FDA Confident As Review Goals Near

Executive Summary

Review metrics go into effect in another year, but times continue to increase; FDA and others still believe they are well on their way to meeting the generic drug user fee goals.

Advertisement

Related Content

PDUFA Communications Hurt By Sequestration As Late-Stage Meetings Begin
ANDA Sponsors May Need Extra Three Months To Avoid DMF-Related Delays
Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections

Topics

Advertisement
UsernamePublicRestriction

Register

PS055632

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel